No Third Party Patents. Except as disclosed in writing by NOVARTIS to VERTEX or its agents, to NOVARTIS' knowledge and based on its current understanding of the Drug Product Candidate(s) and its use, the manufacture, use or sale of any Bulk Drug Substance, Drug Product Candidates or Drug Products pursuant to this Agreement will not infringe or conflict with any Third Party right or patent, and NOVARTIS is not aware of any issued patent or pending patent application that, if issued, would be infringed by the development, manufacture, use or sale of any Bulk Drug Substance, Drug Product Candidates or Drug Products pursuant to this Agreement.
No Third Party Patents. To ACI’s knowledge, the making, using, importing, offering for sale, keeping or selling of Products pursuant to this Agreement will not infringe or conflict with any Patent Rights of a Third Party.
No Third Party Patents. To Vertex’s knowledge, no Third Party right or patent would necessarily be infringed by the Development, Manufacture, use or Commercialization of VX-950 pursuant to this Agreement, and Vertex is not aware of any pending patent application that, if issued, would necessarily be infringed by the Development, Manufacture, use or Commercialization of VX-950 pursuant to this Agreement.
No Third Party Patents. Except as disclosed in writing by Avalon to Vertex or its agents, to Avalon’s knowledge and based on its current understanding of the Compound(s) and its use, the manufacture, use or sale of any Bulk Drug Substance, Compound or Drug Products pursuant to this Agreement will not infringe or conflict with any Third Party right or patent, and Avalon is not aware of any issued patent or pending patent application that, if issued, would be infringed by the development, manufacture, use or sale of any Bulk Drug Substance, Compound or Drug Products pursuant to this Agreement.
No Third Party Patents. 37 9.4 Maintenance of Patents and Licenses....................... 37 ARTICLE X--Representations and Warranties of SCHERING.......... 37
No Third Party Patents. To Vertex's knowledge, except as disclosed in Schedule 9.1.3, the development, manufacture, use or sale of VX-409 and any Back-up Compounds pursuant to this Agreement does not infringe or conflict with any Third Party right or patent, and Vertex is not aware of any pending patent application that, if issued, would be infringed by the development, Information redacted pursuant to a confidential treatment request. An unredacted version of the exhibit has been filed separately with the Commission. manufacture, use or sale of VX-409 or any Back-up Compounds pursuant to this Agreement. Vertex has informed GSK that Vertex has not conducted an extensive review of Third Party intellectual property relative to the Back-up Compounds.
No Third Party Patents. Except as disclosed in writing by Cell Genesys to Novartis or its agents as of the Effective Date, to the knowledge of Cell Genesys, the development, manufacture, use or sale of the Option Product pursuant to this Development License and Commercialization Agreement will not infringe or conflict with any Third Party right or patent, and Cell Genesys is not aware of any Third Party patent or pending patent application that, if issued, would be infringed by the development, manufacture, use or sale of any Option Product.
No Third Party Patents. Except as disclosed in writing by SCHERING to VERTEX or its agents, to SCHERING's knowledge and based on its current understanding of the Drug Product Candidate(s) and its use, the manufacture, use or sale of any Bulk Drug Substance, Drug Product Candidates or Drug Products pursuant to this Agreement will not infringe or conflict with any Third Party right or patent, and SCHERING is not aware of any pending patent application that, if issued, would be infringed by the development, manufacture, use or sale of any Bulk Drug Substance, Drug Product Candidates or Drug Products pursuant to this Agreement.
No Third Party Patents. As of the Effective Date, to Bago's actual knowledge and based on its current understanding of the Product and its use, in the development, manufacture, use or sale of any Product pursuant to this Agreement will not infringe or conflict with any Third Party right or Patent, and as of the Effective Date Bago is not aware of any pending patent application that, if issued, would be infringed by the development, manufacture, use or sale of any Product pursuant to this Agreement.
No Third Party Patents. As of the Effective Date, to Genaera's actual knowledge and based on its current understanding of the Product, and its use, in the manufacture, use or sale of any Product pursuant to this Agreement will not infringe or conflict with any Third Party right or Patent, and as of the Effective Date Genaera is not aware of any pending patent application that, if issued, would be infringed by the development, manufacture, use or sale of any Product pursuant to this Agreement.
